C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · IEX Real-Time Price · USD
6.03
-0.22 (-3.52%)
At close: Jul 19, 2024, 4:00 PM
6.17
+0.14 (2.32%)
Pre-market: Jul 22, 2024, 7:24 AM EDT
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $20.04M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $3.04M. In the year 2023, C4 Therapeutics had annual revenue of $20.76M.
Revenue (ttm)
$20.04M
Revenue Growth
-26.34%
P/S Ratio
20.71
Revenue / Employee
$138,179
Employees
145
Market Cap
414.90M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 20.76M | -10.34M | -33.25% |
Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
Dec 31, 2018 | 19.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Health Catalyst | 296.79M |
Sonida Senior Living | 260.69M |
Esperion Therapeutics | 229.74M |
Cerus | 191.72M |
Anika Therapeutics | 169.26M |
Editas Medicine | 69.41M |
Taysha Gene Therapies | 14.16M |
Ocugen | 7.05M |
CCCC News
- 5 days ago - C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 - GlobeNewsWire
- 14 days ago - C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day - GlobeNewsWire
- 6 weeks ago - C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors - GlobeNewsWire
- 2 months ago - C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum - GlobeNewsWire
- 3 months ago - C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 4 months ago - C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire